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A combination of ﬂudarabine (Flu) and daily i.v. busulfan (Bu) is well tolerated and effective in patients
undergoing allogeneic hematopoietic stem cell transplantation. Although there is some evidence that
Bu exposures exceeding 6000 mM/min may lead to excessive toxicity, there is little information on the effect
of exposures below this level on outcomes. We studied Bu exposure, as measured by area under the
concentration-time curve (AUC), in 158 patients with various hematologic malignancies in an attempt
to identify an optimal range for targeted therapy. The preparative chemotherapy regimen comprised Flu
50 mg/m2 on days -6 to -2 and i.v. Bu 3.2 mg/kg on days -5 to -2 inclusive. Graft-versus-host disease (GVHD)
prophylaxis included methotrexate, cyclosporin A, and antithymocyte globulin. Patients with Bu exposures
below the median AUC of 4439 mM/min were at increased risk for acute GVHD grade II-IV (hazard ratio [HR],
2.30; 95% conﬁdence interval [CI], 1.19 to 4.49; P ¼ .014). Those in the highest and lowest Bu exposure
quartiles (daily AUC <3814 mM/min and >4993 mM/min) had an increased risk of nonrelapse mortality
(subdistribution HR, 3.32; 95% CI, 1.46 to 7.54; P ¼ .004), as well as worse disease-free survival (HR, 1.81; 95%
CI, 1.09 to 2.99; P ¼ .021) and overall survival (HR, 1.94; 95% CI, 1.12 to 3.37; P ¼ .018). Bu exposures between
4440 and 4993 mM/min were accompanied by the lowest risk of both nonrelapse mortality and acute GVHD.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION myeloablative Flu/Bu regimen between August 2000 and July 2011 for
Although i.v. busulfan (Bu) has more predictable phar-
macokinetics than the oral form, there remains at least a 3- to
4-fold variation in exposure between patients given the same
dose based on weight [1]. A combination of ﬂudarabine (Flu)
and daily i.v. Bu at myeloablative doses has proven well
tolerated and effective in patients undergoing allogeneic
hematopoietic stem cell transplantation (HSCT) [2-11]. With
this regimen, there is some evidence that Bu exposures
exceeding 6000 mM/min are excessive, but there is little
information on the effect of exposures below this level on
outcomes [12]. As part of a routine program of therapeutic
dose monitoring (TDM), we measured Bu exposure, as
expressed by the area under the concentration-time curve
(AUC), inpatients receiving a Flu/Bu regimenbeforeHSCT. The
present study examined whether different exposures below
6000 mM/min have any inﬂuence on clinical outcomes, with
the goal of deﬁning an appropriate range for targeted therapy.PATIENTS AND METHODS
Patients
This study is a retrospective analysis of outcomes of 158 consecutive
adults with hematologic malignancies treated with HSCT after adgments on page 1385.
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13.07.002whom TDMwas performed and Bu exposurewas<6000 mM/min. Diagnoses
and details of the HSCTs are presented in Table 1. Patients were divided into
4 quartile groups according to total Bu exposure. Seventeen patients with
acute leukemia were excluded, because our standard regimen now includes
400 cGy total body irradiation (TBI) for these patients [2,13,14]. Distribution
of risk factors was similar across the 4 groups apart from the proportion of
patients with chronic myelogenous leukemia (CML) in chronic phase (CP)
1 (0% in group 4 vs 16% in groups 1 to 3; P ¼ .02). Surviving patients were
followed for a median of 51 months (range, 12 to 142 months).
Treatment
The preparative chemotherapy comprised Flu 50 mg/m2 on days -6 to -2
and i.v. Bu (Busulfex; Otsuka America Pharmaceutical, Princeton, NJ)
3.2 mg/kg (based on the lower of actual or adjusted ideal body weight) on
days -5 to -2 inclusive. Supportive care was similar for all patients. No
protective isolation was used [15]. Platelets were administered to maintain
a platelet count >10  109/L, and RBCs were administered to maintain
a hemoglobin level >80 g/L. Growth factors were not routinely adminis-
tered. All patients received trimethoprim/sulfamethoxazole as prophylaxis
for Pneumocystis jirovecii. Antibacterial prophylaxis was provided with
ciproﬂoxacin 500 mg twice daily until 2003, after which time no antibac-
terial antibiotics were given routinely. All blood products were cytomega-
lovirus (CMV)-safe. A policy of surveillance for pp65 antigen or CMV
polymerase chain reaction, followed by preemptive therapy with ganciclovir
when indicated, was used when the donor and/or recipient were CMV
antibody-positive. Routine monitoring for Epstein-Barr virus viral load was
not done. The acute graft-versus-host disease (aGVHD) prophylaxis protocol
included cyclosporin A (CsA) orally or i.v. twice daily to maintain blood
levels between 150 and 400 mol/L. Methotrexate was given at 15 mg/m2 i.v.
on day 1 and at 10 mg/m2 on days 3, 6, and 11. Folinic acid 5 mg i.v. or orally
was started at 24 hours after each methotrexate dose and continued every
6 hours until 12 hours before the next dose. In addition, all patients were
given rabbit antithymocyte globulin (ATG; Thymoglobulin; Sanoﬁ, Paris,Transplantation.
Table 1
Patient and Transplant Characteristics
Characteristic Group (Range of Bu Exposure (mM/min) Total
1 (2184-3813) 2 (3814-4439) 3 (4440-4993) 4 (4994-5995)
Number 39 (100) 40 (100) 40 (100) 39 (100) 158 (100)
Patient age, yr, median (range) 50 (30-65) 52 (20-64) 50 (29-65) 51 (18-66)
Male patient, n (%) 25 (64) 25 (63) 27 (68) 30 (77) 107 (68)
Low-risk disease (CML CP), n (%) 5 (13) 7 (18) 7 (18) 0* 19 (12)
High-risk disease, n (%) 34 (87) 33 (83) 33 (83) 39 (100) 139 (88)
CML AP 1 (3) 2 (5) 1 (3) 3 (8) 7 (4)
CLL/SLL 9 (23) 10 (25) 10 (25) 3 (8) 32 (20)
Myelodysplastic syndrome 7 (18) 6 (15) 6 (15) 7 (18) 26 (16)
Multiple myeloma 0 0 1 (3) 5 (13) 6 (4)
Non-Hodgkin lymphoma 7 (18) 7 (18) 10 (25) 14 (36) 38 (24)
MF/MPD 8 (21) 5 (13) 2 (5) 3 (8) 18 (11)
Hodgkin disease 1 (3) 1 (3) 2 (5) 2 (5) 6 (4)
Waldenstrom macroglobulinemia 1 (3) 1 (3) 1 (3) 1 (3) 4 (3)
Hairy cell leukemia 0 1 (3) 0 0 1 (1)
T cell prolymphocytic leukemia 0 0 0 1 (3) 1 (1)
Donor, n (%)
Matched related 26 (67) 24 (60) 17 (43) 23 (59) 90 (57)
Mismatched related 0 0 3 (8) 0 3 (2)
Matched unrelated 8 (21) 10 (25) 14 (35) 13 (33) 45 (28)
Mismatched unrelated 5 (13) 6 (15) 6 (15) 3 (8) 20 (13)
CMV antibody-positive recipient or donor, n (%) 27 (69) 31 (78) 26 (67)y 26 68)y 110 (70)y
Female-to-male HSCT, n (%) 13 (33) 13 (33) 10 (25) 13 (33) 49 (31)
Blood as stem cell source, n (%) 33 (85) 38 (95) 35 (88)z 36 (92)z 142 (90)
HCT-CI score 1, n (%) 12 (31) 12 (30) 11 (28) 10 (27) 45 (28)
AP indicates accelerated phase; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma with or without Richter’s transformation.
* P ¼ .004 for CML CP in group 4 versus groups 1, 2, and 3.
y One patient/donor with unknown status.
z Remainder bone marrow except for 1 cord blood in groups 2 and 3.
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a continuous infusion over 4 to 8 hours. To minimize reactions, the ﬁrst dose
was reduced to 0.5 mg/kg, and the next 2 doses were 2 mg/kg, with the ﬁnal
infusion given on the day of transplantation. Premedication included
methyprednisolone 40 mg i.v. every 12 hours for 6 doses and benadryl
50 mg i.v. before each dose of ATG.
Therapeutic Dose Monitoring
A total of 123 patients were given a test dose of Bu at 2 to 5 days before
the treatment dose, as described previously [16]. Fifteen patients received
a test dose of Bu 12 mg over 20 minutes, 3 received a test dose of 0.8 mg/kg
over 3 hours, and the remaining 105 received a test dose of 0.8 mg/kg at
a rate of 80 mg/hour according to our current protocol. Nine patients (1 in
group 2, 4 in group 3, and 4 in group 4) had a dose adjustment to target
5000 mM/min if the test dose predicted an exposure exceeding 5500 mM/
min. This allowed a margin of error to ensure the therapeutic dose exposure
remained below 6000 mM/min. No other patients had a dose adjustment
based on the test dose. Total daily exposure was calculated to include one-
quarter of the test dose exposure.
Engraftment
Daily blood counts were performed until discharge, with bone marrow
aspirations done at 3 months for surviving patients and thereafter as clini-
cally indicated. Granulocyte engraftment was deﬁned as a count of
>0.5  109/L for 3 consecutive days. The platelet count needed to exceed
20  109/L without transfusion for 7 days.
GVHD
aGVHD was graded according to standard criteria [17]. Grading was
performed by physicians at onset and during treatment, with later conﬁr-
mation and recording by data managers. aGVHD was treated with predni-
sone or methylprednisolone initially while continuing CsA. First-line
therapy for steroid-resistant aGVHD was ATG 2 mg/kg every other day for 2
to 4 doses while CsAwas withheld. Chronic GVHD (cGVHD)was treatedwith
prednisone with or without CsA, with the introduction of other agents if
response was incomplete.
Statistical Analysis
Continuous data are presented as median and range, and categorical
data are presented as count and percentage. Bu exposures were compared
using a 2-tailed t-test. The survivorship function of time-to-event data was
estimated using the product-limit method and compared using the log-ranktest. For analysis of time to nonrelapsemortality (NRM), patients were right-
censored at time of relapse, and for analysis of onset of cGVHD, patients
were right-censored at the time of death, donor lymphocyte infusion, or
second HSCT. Clinical endpoints of relapse, NRM, disease-free survival (DFS),
and overall survival (OS) were recorded at 3 years from HSCT. Univariate
analysis was performed with GraphPad Prism (GraphPad Software,
San Diego, CA).
Cox multivariate proportional hazards regression was used to identify
factors associated with time to death, aGVHD, cGVHD, and the composite
outcome of death or relapse. The standard hazard ratio (HR) and associated
95% conﬁdence interval (CI) was used to measure the strength of the asso-
ciation. For the competing endpoints of relapse and NRM, multivariate
competing-risks regression was used, and the subdistribution hazard ratio
(SHR) with 95% CI was used to describe the association, given that the
standard proportional hazards approach has been shown to be methodo-
logically inadequate when outcomes are competing [18]. All multivariate
analyses were performed using Stata version 11.2 (StataCorp, College
Station, TX). For all analyses, P values <.10 are reported as trends, and
P values <.05 are considered statistically signiﬁcant.
RESULTS
Bu Exposure
The median Bu exposure of all patients was 4439 mM/min
(range, 2184 to 5995 mM/min), with ﬁrst (25%) and third
(75%) quartiles of 3824 and 4994 mM/min, respectively. Mean
exposure was 4373  835 mM/min. Compared with the
remaining patients, those with myeloﬁbrosis/myeloprolifer-
ative disorder (MF/MPD) had lower exposures (mean,
3960  236 mM/min versus 4426  68 mM/min; P ¼ .03), and
those with non-Hodgkin lymphoma had higher exposures
(mean, 4619  134 mM/min versus 4289  76 mM/min;
P ¼ .04). Although there were no patients with CML CP in
group 4, compared with 19 of 119 in groups 1 to 3 (P ¼ .004),
there was no difference in mean AUC between the patients
with CML CP and other patients.
Engraftment
There was no difference in time to engraftment across the
4 groups (Table 2). In the ﬁrst quartile, there were 3 cases of
Table 2
Granulocyte and Platelet Engraftment
Group (n) Granulocytes Platelets
Granulocyte
Engraftment, Days
Failure to Engraft, n Platelet Engraftment,
Days
Failure to Engraft (in the Presence of
Granulocyte Engraftment), n
Median Range Median Range
1 (39) 16 11-26 2 graft failures, second HSCT,
days 68 and 79
18 0-45 1, second HSCT, day 72
2 (40) 15 10-25 1 graft failure (faulty product),
second HSCT, day 21
18 0-54
3 (40) 15 10-32 1 NRM, day 32 18 0-33 1 NRM, day 31
4 (39) 15 10-22 18 0-60 3 NRM, days 19, 40, and 68
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HSCT, compared with 0 in the other 3 quartiles (P¼ .01). Two
of the affected patients had MF/MPD, and 1 patient had
chronic myelomonocytic leukemia. Other cases of failed
engraftment were attributed to a faulty product (n ¼ 1) or
other causes of NRM (n ¼ 5).75
100GVHD
Incidence data for aGVHD and cGVHD are provided in
Table 3 and Figure 1. Patients with Bu exposures below the
median had more than twice the risk of developing grade II-
IV aGVHD (HR, 2.30; 95% CI, 1.19 to 4.49; P ¼ .014) compared
with patients with higher Bu exposures, accounting for
differences in risk group, donor matching, cell type, CMV
status of donor or recipient, female-to-male HSCT, and
a Hematopoietic Cell Transplantation Comobodity Index
(HCT-CI) 1. A similar observation was made for grade III-IV
aGVHD; however, the difference failed to reach statistical
signiﬁcance (HR, 2.25; 95% CI, 0.85 to 5.97; P ¼ .102). There
was no difference in the time to cGVHD across the quartiles.0 25 50 75 100 125
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At 3 years, NRM varied between 13% and 34% across the 4
groups (Table 4). Patients in the highest and lowest quartiles
had a signifantly higher risk of NRM compared with patients
with intermediate Bu exposures (SHR, 3.32; 95% CI, 1.46 to
7.54; P ¼ .004) after adjustment for risk group, donor
matching, cell type, CMV status, female-to-male HSCT, and
HCT-CI1.Moreover, the 3-year rate ofNRMwas signiﬁcantly
higheramong thosewith thehighest and lowest Buexposures
(outside a range of 3814 to 4993 mM/min) compared ot those
with intermediate exposures (31% versus 15%; P ¼ .02,
Figure 2C). Table 5 lists the causes of nonrelapse death. a
GV
H
D
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Relapse rates did not appear to be affected by Bu exposure
(Table 4 and Figure 3) even after adjustment for other risk
factors.Table 3
GVHD
Group (n) aGVHD
Grade II-IV, %
aGVHD
Grade III-IV, %
cGVHD, %
1 (39) 40 18 65
2 (40) 39 18 65
3 (40) 16 5 59
4 (39) 22 11 61
1 and 2 (79) 39* 18y 65
3 and 4 (79) 19* 8y 60
* P ¼ .008.
y P ¼ .07.DFS and OS
Patients in the middle 2 quartiles had better DFS (HR,
1.81; 95% CI, 1.09 to 2.99; P ¼ .021) and OS (HR, 1.94; 95% CI,
1.12 to 3.37; P ¼ .018) than those in the highest and lowest
quartiles (Table 4 and Figure 2A and 2B), after adjustment for
risk group, donor matching, cell type, CMV status, female-to-
male HSCT, and HCT-CI 1.DISCUSSION
Our results indicate that there may be a therapeutic
windowwith better OS, DFS, and NRM at a daily Bu exposure
between 3814 and 4994 mM/min following the study
regimen. This conclusion is consistent with early studies of
oral Bu with cyclophosphamide. In those studies, however,Days
%
0 25 50 75 100 125
0
25
Figure 1. Kaplan-Meier plots of grade II-IV aGVHD (A) and grade III-IV aGVHD
(B). Groups 1 and 2 (solid line) had a Bu AUC below the median, whereas
groups 3 and 4 (dotted line) had a Bu AUC above the median.
Table 4
OS, DFS, NRM, and Relapse
Group (n) OS, % DFS, % NRM, % Relapse, %
1 (39) 61 54 32 21
2 (40) 72 64 17 22
3 (40) 71 70 13 19
4 (39) 56 40 34 38
1 and 4 (78) 61 47* 31* 29
2 and 3 (80) 79 67* 15* 21
* P ¼ .02.
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related toxicity and lower Bu exposures were associated
with more relapse and graft failuredoutcomes that could be
predicted on theoretical grounds [19-21]. Likewise, Ander-
sson et al. [22] reported improved outvcomes in patients
with CML receiving i.v. Bu every 6 hours with cyclophos-
phamide, with a per-dose AUC betweenw950 and 1520 mM/
min. Our conclusions are similar, but remain difﬁcult to
interpret completely.
Our ﬁnding of an increased incidence of aGVHD with
lower Bu exposure was somewhat unexpected. More aGVHD
was seen in both quartiles 1 and 2 and less in quartiles 3 and
4, so the observation seems unlikely to be an artifact.
Whether an unbalanced representation of different diag-
noses in the 4 groups could have contributed to this ﬁnding is
hard to say, given the relatively small numbers involved.
Experimental evidence suggests that more intensive condi-
tioning will lead to more aGVHD via mechanisms involving
cytokine release [23]. In general, reduced-intensity and
nonmyeloablative conditioning is followed by less aGVHD
compared with fully myeloablative regimens. More speciﬁ-
cally, Andersson et al. [22], using a Bu-cyclophosphamide
regimen for CML, found an increase in aGVHD and other
toxicities with higher i.v. Bu exposures.
We have no evidence that Bu exposure is directly or
indirectly associatedwith the activity of other components of
the GVHD prophylaxis regimen. It is conceivable that lower
exposure to Bu could allow the persistence of more host
dendritic cells, which are known to be relatively resistant to
cytotoxic agents and to contribute to aGVHD in animal
models [24]. In a study of 109 patients with acute myeloge-
nous leukemia (AML) treated with our Flu/Bu regimen and
400 cGy TBI, Lewis et al. [25] reported no signiﬁcantTable 5
Primary Causes of Nonrelapse Death
Group
(n)
Death before Day
100 (n)*
Death after Day
100 (n)*
Total
Deaths
1 (39) Graft failure (1)
GVHD-related (1)
ARDS (1)
Graft failure (2)
GVHD-related (5)
Infection/second
malignancy (1)
11
2 (40) PTLPD (1)
GVHD (4)
Infection (1)
6
3 (40) GVHD related (2)
Infection/multiorgan
failure (1)
Cerebral hemorrhage (1)
Secondary graft
failure/PTLPD (1)
5
4 (39) Infection (4)
PTLPD/infection (1)
GVHD-related (1)
GVHD-related (4)
Infection (1)
ARDS (1)
12
ARDS indicates adult respiratory distress syndrome; PTLPD, post-
transplantation lymphoproliferative disease.
* Includes identiﬁed opportunistic infection when death was GVHD-
related.
Months
0 24 48 72 96 120 144
Figure 2. Kaplan-Meier plots of OS (A), DFS (B), and NRM (C). Groups 1 and 4
(dotted line) had a Bu AUC outside the range of 3814 to 4993 mM/min, whereas
groups 2 and 3 (solid line) had a Bu AUC within that range.difference in aGVHD with exposures above or below the
median. This discrepancy would be consistent with the
added effect of TBI on suppression of host dendritic cells in
patients with the lower Bu exposures. It may be that our
ﬁndings are relevant only with the conditioning and GVHD
prophylaxis speciﬁc to this regimen, and that the diseases
involved (AML versus other) may inﬂuence the outcome.
Examining the causes of NRM does not clearly explain the
relationship of NRM to Bu exposure. The only cases of graft
failure occurred in quartile 1, but the diseases treated also
may have contributed to poor engraftment. The higher
incidence of aGVHD in groups 1 and 2 is not reﬂected in
aGVHD as the primary cause of NRM.
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Figure 3. Kaplan-Meier plots of relapse.
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geneity of diagnoses and some differences in exposures by
disease. Moreover, the expectation that relapse should
decrease with increased conditioning intensity is based in
large part on studies of patients with AML, a condition not
included in this analysis. We also know that relapse may be
inﬂuenced by a graft-versus-malignancy (GVM) effect.
Conceivably, a trend to less relapse with higher Bu exposures
could be masked by a tendency for patients with lower
exposures to experience more GVM, although GVM is usually
attributable to cGVHD rather than aGVHD.
A previous study found signiﬁcantly increased NRM at
daily Bu exposures >6000 mM/min [12]. Below this level, no
trend toward different levels of NRMwas seenwhen the data
were analyzed by, for example, quartiles as in the present
study. The earlier patient group included those with acute
leukemia receiving 400 cGy TBI in addition to Bu/Flu. TBI did
not inﬂuence NRM in that study. When patients with AML
were treated with additional TBI, NRM was signiﬁcantly
higher with Bu exposures above the median [25]. The
discrepancies between these 2 studies might be explained by
the smaller numbers of patients with andwithout AML in the
initial series plus, perhaps, effects of TBI and/or the disease
under investigation on outcomes.
We found that Bu exposures were lower in patients with
MF/MPD and higher in those with non-Hodgkin lymphoma.
Whether this ﬁnding relates simply to the disease per se, or
also to other factors, such as previous chemotherapy, we
cannot say. There appeared to be no impact of disease on
NRM, although the numbers of individual diagnoses could be
too low to allow detection of such an inﬂuence.
Our analysis did not examine outcomes over the whole
range of exposures achieved when patients are given Bu
doses based on weight, because of our data suggesting that
exposures above 6000 mM/min may be harmful. However,
only 9 patients had a dose adjustment to bring exposure
below this level, and the conclusion that optimum exposure
may be below 5000 mM/min is unlikely to be affected.
Other investigators have suggested that the safety
threshold for daily Bu exposure with a Bu/Flu combination
may be as high as 7500 mM/min [8]. This conclusion was
arrived at by adjusting exposures on days 3 and 4 to
successively higher levels rather than through a retrospec-
tive analysis. Whether the different conclusions are related
to study design or the small numbers of patients experi-
encing high exposures in both studies is uncertain. There
have been relatively few attempts at determining the
optimum i.v. Bu exposure in diseases other than CML.
Andersson et al. [26] reported less disease progression inpatients with advanced AML with exposure targeted to
6000 mM/min compared with those with a ﬁxed dose
providing a median exposure of w5000 mM/min. Toxicity
was not increasedwith the higher exposure [26]. Others have
reported that daily exposures below 6000 mM/minwere well
tolerated and effective in acute leukemias and, with rituxan,
in lymphoma [9-11]; however, those studies used arbitrary
(albeit rational) targets of Bu exposure rather than deter-
mining what an optimum range of exposure might be.
In conclusion, this study conﬁrms the importance of TDM
of i.v. Bu. Targets for Bu AUC may vary with other speciﬁc
cytotoxic and immunosuppressive components of the
conditioning protocol and also according to the disease being
treated. Thus, it is difﬁcult to state more than tentative
conclusions until more data are available. Some of the
shortcomings of this analysis could be overcome by
prospective studies randomizing patients to receive
different, targeted Bu exposures where the groups are
balanced for diagnosis. For now, with the current regimen
used under the conditions studied here, it seems reasonable
to target daily exposure between 4440 and 4993 mM/min to
minimize NRM and the morbidity of aGVHD.ACKNOWLEDGMENTS
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